Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group LtdfiledCriticalGlaxo Group Ltd
Publication of CR20120103ApublicationCriticalpatent/CR20120103A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Se describen 4-amino-2-butenamidas de la Fórmula (I) que tienen actividad farmacológica, composiciones farmacéuticas que las contienen, y métodos para el tratamiento de enfermedades mediadas por la enzima catepsina C tales como la enfermedad pulmonar obstructiva crónica.4-Amino-2-butenamides of Formula (I) having pharmacological activity, pharmaceutical compositions containing them, and methods for the treatment of diseases mediated by the enzyme cathepsin C such as chronic obstructive pulmonary disease are described.
CR20120103A2009-08-122012-02-28
CATEPSIN C INHIBITORS
CR20120103A
(en)
Compounds derived from isoindol-amide, pyrrolo-pyridin-amide and pyrrolo-pyrimimidin-amide, nampt and rock inhibitors; pharmaceutical composition; and method to treat hyperetension, chronic heart failure, atherosclerosis, asthma, Alzheimer's disease, parkinson's disease and glaucoma, among other diseases.
a method for preparing a plasma erected alpha-inhibitor (aiip) composition, aqueous iaip solution, and a method for treating a disease or disorder associated with iaip dysfunction and associated with increased plasma serine protease activity.